Drug profile · INN
infigratinib phosphate
TRUSELTIQ
infigratinib phosphate (TRUSELTIQ) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — infigratinib phosphate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
infigratinib phosphate (TRUSELTIQ) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Fibroblast growth factor receptor inhibitor
Primary target: Fibroblast growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is infigratinib phosphate?
infigratinib phosphate (TRUSELTIQ) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for infigratinib phosphate?
TRUSELTIQ is a marketed brand name for infigratinib phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of infigratinib phosphate?
infigratinib phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.